Results 71 to 80 of about 5,054 (206)

Evaluation of Discontinuation and Re‐Initiation of Biologic Therapies in Psoriasis: Real‐World Data

International Journal of Dermatology, EarlyView.
The cumulative probability of remaining relapse‐free following biologic therapy discontinuation was 35.6%, 19%, 11.6%, and 9.1% at 6, 12, 18, and 24 months, respectively. Prolonged relapse durations were associated with a low baseline PASI score, the presence of a PASI 90 response at discontinuation, the absence of triggering factors, and the use of IL‐
Ahmet Taha Aydemir, Nihal Kundakcı
wiley   +1 more source

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

, 2023
Background Biologics have revolutionized the management of psoriasis, but response to treatment varies. Loss of treatment efficacy may occur over time, requiring treatment switching or escalation.
Dominic Pilon, Patrick Lefebvre, Aditi Shah, Maryia Zhdanava, Steven R. Feldman, Timothy Fitzgerald, Annalise Hilts   +6 more
core   +1 more source

Darier disease—A review highlighting new insights from the Darier Disease International Task Force

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review provides a global, clinically focused overview of DD, detailing cutaneous and extracutaneous manifestations, disease classification and severity scoring. It emphasizes early recognition, multidisciplinary management and practical guidance for dermatologists to apply evidence‐based care in diverse skin phototypes. Abstract Darier disease (DD)
Sofia Labbouz, Alain Hovnanian, Grace Xiong, Dedee Frances Murrell, Simon M. Mueller, Khaled Ezzedine, Nessa Aghazadeh Mohandesi, Ahmed Salem Aldhaheri, Nissim Asayag, Eulalia Baselga, Chen Nadler, Keith Choate, Chia‐Yu Chu, John Robert Edminister, Emmanuella Guenova, Melis Gönülal, Antoni Gostynski, Ankan Gupta, Lalit Kumar Gupta, Juliette Mazereeuw‐Hautier, Wolfram Hoetzenecker, Peter Itin, Marek Jankowski, Akiharu Kubo, Haur Yueh Lee, Julia Scott Lehman, Anfisa Lepekhova, Márta Medvecz, Jemima E. Mellerio, Verena Moosbrugger‐Martinz, Amy S. Paller, Dóra Plázár, Amadeu José Rodrigues Queiróz, Josep Riera‐Monroig, Ralph Rosa, Matthias Schmuth, Maella Severino Freire, Itzhak Shabat, Jonathan Shapiro, Cory L. Simpson, Diego Soto‐García, Alexander J. Stratigos, Gianluca Abel Tadini, Takuya Takeichi, Kaushal K. Verma, Jakob D. Wikström, Alexander Zink, Michael Ziv, Alexander Navarini, Roni Pircha Dodiuk‐Gad   +49 more
wiley   +1 more source

บทบาทของยา Guselkumab ในการรักษาโรคสะเก็ดเงินชนิดผื่นหนา Role of Guselkumab for the Treatment of Plaque Psoriasis [PDF]

บทคัดย่อ   Guselkumab เป็นยารักษาโรคสะเก็ดเงินชนิดผื่นหนาระดับปานกลางถึงรุนแรงในผู้ใหญ่อายุ 18 ปีขึ้นไป ที่ต้องได้รับการรักษาด้วย systemic therapy หรือ phototherapy ซึ่งเป็นยารายการแรกในกลุ่ม Interleukin-23 inhibitor ที่ได้รับการอนุมัติจากองค ...
Suncharoen, Sirada
core  

Guselkumab as a Successful Fourth-Line Therapy

Guselkumab is a monoclonal antibody that selectively inhibits the p19 subunit of interleukin-23, providing a targeted mechanism for controlling inflammatory pathways in psoriasis and psoriatic arthritis.
Svetlana Popadić, Marko Demenj, Anđela Kovčić, Branislav Lekić   +3 more
core   +1 more source

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Selective IL‐23 Inhibition in Conventional Treatment‐Refractory Pyoderma Gangrenosum: A Multicenter, Retrospective Study

International Journal of Dermatology, Volume 65, Issue 10, Page 2055-2065, October 2026.
The clinical effects of selective IL‐23 inhibition in refractory pyoderma gangrenosum, highlighting progressive ulcer healing, reduction in inflammation and pain, and steroid‐sparing effect, supporting the role of the IL‐23/Th17 axis as a therapeutic target.
Luca Bettolini, Carlo Alberto Maronese, Federica Derlino, Giovanni Genovese, Chiara Moltrasio, Luisa Sarno, Stefano Buffon, Bianca Cei, Giammarco Granieri, Valentina Dini, Marco Romanelli, Vincenzo Maione, Stefano Bighetti, Marina Venturini, Edoardo Cammarata, Paola Savoia, Antonio Di Guardo, Luigi Gargiulo, Ruggero Cascio Ingurgio, Antonio Costanzo, Lorenza Burzi, Claudia Leporati, Nunzia Di Cristo, Nicola Zerbinati, Alex G. Ortega‐Loayza, Angelo Valerio Marzano   +25 more
wiley   +1 more source

Impact of Selective Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK‐279) on Molecular Pathways and Correlated Clinical Response in Patients With Active Psoriatic Arthritis

ACR Open Rheumatology, Volume 8, Issue 9, September 2026.
Objective This post hoc analysis evaluated the effect of zasocitinib, an investigational, oral, allosteric, highly selective, and potent tyrosine kinase 2 (TYK2) inhibitor in late‐stage clinical development, on TYK2 signaling response and disease‐related biomarkers and the association of these changes with clinical response in patients with active ...
Amit Choudhury, Jie Cheng, Jay Tang, Sachin Kumar, Banishree Saha, Vinayagam Arunachalam, Ting Hong, Ejim Mark, Håkan Wennbo, Iain B. McInnes   +9 more
wiley   +1 more source

Artificial Intelligence Resources for the Screening of Titles and Abstracts in Systematic Reviews: A Scoping Review

Cochrane Evidence Synthesis and Methods, Volume 4, Issue 5, September 2026.
ABSTRACT Introduction Artificial intelligence (AI) is a branch of technology enabling machines to emulate complex human skills; it can also entail problem‐solving using bioinspired methods. It is used for automating systematic literature reviews (SLR), that is, defining a clinical question, locating relevant literature, preliminary screening, study ...
Ana M. Barragán, Sara Elena Ortiz Bonett, Eliana‐Isabel Rodríguez‐Grande, Alvaro David Orjuela‐Cañón, Oscar J. Perdomo, Guillermo Sánchez‐Vanegas   +5 more
wiley   +1 more source

Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials

Rheumatology and Therapy
Introduction Patterns of treatment response can inform clinical decision-making. This study assessed the course and impact of achieving minimal clinically important improvement (MCII) in clinical measures and patient-reported outcomes (PROs) with ...
Jeffrey R. Curtis, Atul Deodhar, Enrique R. Soriano, Emmanouil Rampakakis, May Shawi, Natalie J. Shiff, Chenglong Han, William Tillett, Dafna D. Gladman   +8 more
doaj   +1 more source